Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting

Eşkazan, Ahmet Emre; Ali, Rıdvan; Alnıgeniş, Ebru; Ayyıldız, Orhan; Haznedaroğlu, İbrahim C.; Kırkızlar, Onur; Kurtoğlu, Erdal; Malhan, S; Öksüz, E; Polat, Özlem; Saydam, Güray; Sönmez, Mehmet; Toprak, Selami Koçak; Toptaş, Tayfur; Turğut, Mehmet

doi:10.1080/17474086.2022.2044779

Cited by 5 publications

(5 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, lack of access and financial issues precluded some experts from ever assessing mutation status. Similar figures were suggested by the Turkish expert group and the TARGET survey, which might imply that those barriers are common across different countries in the region [14,15].…”

Section: Discussion and Expert Opinionsupporting

confidence: 78%

“…Those numbers cannot be confirmed by solid figures, considering the scarcity of studies describing the CML population in the GCC region. Among regional figures, a group of experts from Turkey reported similar estimates of 59%, 27%, and 12% of CML patients receiving first-, second-, and third-line treatment, respectively [ 15 ]. The TARGET survey reported slightly higher numbers in first-line treatment (66%, 25%, and 9%, respectively) [ 14 ].…”

Section: Discussion and Expert Opinionmentioning

confidence: 99%

“…More experts reported changing treatment in the case of Persistent Grade 2 and Grade 3/4 non-hematological toxicities as compared to Persistent Grade 2 and Grade 3/4 hematological toxicities. A previous expert consensus has suggested a potential explanation for this observation, stating that hematologists are more accustomed to handling hematological toxicities as compared to other types of toxicity [ 15 ].…”

Section: Discussion and Expert Opinionmentioning

confidence: 99%

See 2 more Smart Citations

Current Status and Management of Chronic Myeloid Leukemia in the Gulf Region: Survey Results and Expert Opinion

Saglio,

Yassin,

Alhuraiji

et al. 2024

Cancers

View full text Add to dashboard Cite

Studies on chronic myeloid leukemia (CML) in the Gulf region are scarce, consisting of a survey and expert meeting that included 15 experts in 2023 which discussed CML diagnosis, testing, treatment objectives, toxicities, and discontinuation in the Gulf region. Most patients were reported to be in first-line therapy, and the most common treatments were imatinib/imatinib generic in first-line and dasatinib in second- and third-lines. Mutation analysis was not reported to be routinely performed at the time of diagnosis but rather in case of progression to accelerated/blast phase or any sign of loss of response. While all participants were aware that BCR-ABL should be monitored every three months during the first year of treatment, 10% reported monitoring BCR-ABL every six months in practice due to test cost and lab capability. The most important first-line therapy objective was “achievement of major molecular response” (MMR) in younger patients and “overall survival” in older ones. The most important treatment objectives were “MMR” and “early molecular response followed by prolongation of overall survival” in the short term and “treatment-free remission” in the long term. The current practices in CML in the Gulf region appear to be similar to global figures.

show abstract

Section: Discussion and Expert Opinionsupporting

confidence: 78%

Section: Discussion and Expert Opinionmentioning

confidence: 99%

Section: Discussion and Expert Opinionmentioning

confidence: 99%

See 1 more Smart Citation

Current Status and Management of Chronic Myeloid Leukemia in the Gulf Region: Survey Results and Expert Opinion

Saglio,

Yassin,

Alhuraiji

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…While the ELN indicates that a short-term hydroxyurea may be The NCCN considers generic imatinib a suitable substitute for original imatinib due to FDA approval [10]. The ELN places special emphasis on generic imatinib and states that a generic imatinib is an acceptable alternative to brandname imatinib due to its lower price [36][37][38][39][40]. Particularly in the United States, access to generic imatinib via online pharmacies (such as The Mark Cuban Cost Plus Drug Company) permits substantial drug cost reductions and relieves patients' financial burden.…”

Section: First-line Treatmentmentioning

confidence: 99%

Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities

et al. 2022

Self Cite

View full text Add to dashboard Cite

Patients diagnosed with chronic myeloid leukemia (CML) in chronic phase can now have a life expectancy comparable to that of the general population thanks to the use of tyrosine kinase inhibitor (TKI) therapies. Although most patients with CML require lifelong TKI therapy, it is possible for some patients to achieve treatment-free remission. These spectacular results have been made possible by the development of superior treatment modalities as well as clinicians' efforts in strictly adhering to clinical guidelines such as the National Comprehensive Cancer Network (NCCN) and European Leukemia Network (ELN). CML treatment recommendations reported in these guidelines are the result of years of selecting and incorporating the most reliable evidence. In this review, we provide a synopsis of the differences and similarities that exist between the NCCN and ELN guidelines.

show abstract

“…4 This was most likely due to the exclusion of elderly patients concomitantly using drugs that might have affected the imatinib concentration. Although the median age of patients with chronic myeloid leukemia at diagnosis can be 40-50 years in some populations, 6 it is generally 57-60 years. 7 As a result, from my point of view, this cohort does not fully represent ordinary, everyday patients with CML.…”

mentioning

confidence: 99%

Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!

Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting

Cited by 5 publications

References 60 publications

Current Status and Management of Chronic Myeloid Leukemia in the Gulf Region: Survey Results and Expert Opinion

Current Status and Management of Chronic Myeloid Leukemia in the Gulf Region: Survey Results and Expert Opinion

Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities

Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!

Contact Info

Product

Resources

About